Clinical trials
Phase 1/2 Immunoglobulin Light-chain Amyloidosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2005 | 1 |
| 2007 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boston Medical Center | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Cancer Treatment Centers of America | 1 |
| Columbia University | 1 |
| Dana-Farber Cancer Institute | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 1 |
| Nexcella Inc. | 1 |
| OHSU Knight Cancer Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immunoglobulin Light-chain Amyloidosis | 16 |
| Amyloidosis | 5 |
| Multiple Myeloma | 5 |
| Burkitt Lymphoma | 4 |
| Hodgkin Disease | 4 |
| Leukemia, Biphenotypic, Acute | 4 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Leukemia, Myeloid, Acute | 4 |
| Leukemia, Myelomonocytic, Chronic | 4 |
| Lymphoma, B-Cell, Marginal Zone | 4 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.